UCB7665

DRUG2 trials

Sponsors

UCB Biopharma SRL, UCB Biopharma S.P.R.L.

Conditions

Myasthenia GravisThrombocytopenia

Phase 2

Study to Evaluate Safety, Tolerability and Efficacy of UCB7665 in Subjects With Primary Immune Thrombocytopenia

CompletedNCT02718716

UCB Biopharma SRLThrombocytopenia

Start: 2016-03-02End: 2019-02-04Updated: 2024-01-29

Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis

CompletedNCT03052751

UCB Biopharma S.P.R.L.Myasthenia Gravis

Start: 2017-05-15End: 2018-08-06Updated: 2021-08-03

Related Papers

Maintenance of zilucoplan efficacy in patients with generalised myasthenia gravis up to 24 weeks: a model-informed analysis

Therapeutic Advances in Neurological Disorders2024-08-01

Registered trials on novel therapies for myasthenia gravis: a cross-sectional study on ClinicalTrials.gov.

2024-01-243 citations

An evaluation of rozanolixizumab-noli for the treatment of anti-AChR and anti-MuSK antibody-positive generalized myasthenia gravis.

2023-07-014 citations

Measuring Overall Severity of Myasthenia Gravis (MG): Evidence for the Added Value of the MG Symptoms PRO.

2023-05-1116 citations

Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis: A Phase 2 Randomized Control Trial.

2020-11-20113 citations

Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia

Blood Advances2020-09-04107 citations

Rozanolixizumab, an Anti-FcRn Antibody: Final Results from a Phase II, Multiple-Dose Study in Patients with Primary Immune Thrombocytopenia

Blood2019-11-135 citations

S850 SAFETY AND EFFICACY OF AN ANTI‐FCRN ANTIBODY, ROZANOLIXIZUMAB, IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA: INTERIM RESULTS OF A PHASE II, MULTIPLE‐DOSE STUDY

HemaSphere2019-06-013 citations

Proof-of-Concept and Safety of the Anti-FcRn Antibody Rozanolixizumab in Patients with Moderate-to-Severe Generalized Myasthenia Gravis (GMG): A Phase 2a Study (S43.001)

Neurology2019-04-0916 citations

Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration

mAbs2018-08-21110 citations

Phase II, Multiple-Dose Study of Anti-FcRn Antibody, Rozanolixizumab (UCB7665), in Patients with Primary Immune Thrombocytopenia: Interim Analysis

2017-12-0712 citations